racecadotril ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
endopeptidase inhibitors 60 81110-73-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ecadotril
  • acetorphan
  • racecadotril
  • cadotril
  • redotil
A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
  • Molecular weight: 385.48
  • Formula: C21H23NO4S
  • CLOGP: 3.85
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.47
  • ALOGS: -5.34
  • ROTB: 11

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.12 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1993 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rash maculo-papular 101.95 40.83 37 1665 26604 50576818
Acute kidney injury 91.37 40.83 69 1633 227989 50375433
Cholestasis 74.31 40.83 29 1673 25372 50578050
Agranulocytosis 64.56 40.83 25 1677 21396 50582026
Febrile bone marrow aplasia 62.23 40.83 18 1684 6293 50597129
Aplasia 61.43 40.83 16 1686 3797 50599625
Hepatocellular injury 59.92 40.83 25 1677 25922 50577500
Pancytopenia 48.74 40.83 32 1670 83998 50519424
Pancreatitis acute 48.52 40.83 21 1681 23791 50579631
Housebound 47.70 40.83 8 1694 218 50603204
Granulomatous liver disease 44.03 40.83 9 1693 734 50602688
Thrombocytopenia 43.01 40.83 35 1667 127638 50475784

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 108.16 40.51 41 1784 18112 29554590
Hepatocellular injury 105.38 40.51 42 1783 21201 29551501
Alveolar lung disease 95.57 40.51 17 1808 352 29572350
Pulmonary interstitial emphysema syndrome 91.60 40.51 17 1808 449 29572253
Diffuse alveolar damage 71.52 40.51 18 1807 2025 29570677
Eosinophilic pneumonia 60.99 40.51 17 1808 2829 29569873
Acute kidney injury 59.62 40.51 77 1748 265190 29307512
Hyperammonaemia 57.37 40.51 19 1806 5644 29567058
Generalised oedema 51.56 40.51 21 1804 11144 29561558
Eosinophilia 46.27 40.51 24 1801 22137 29550565

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular injury 154.60 32.32 67 3598 45168 64449899
Acute kidney injury 130.85 32.32 143 3522 449097 64045970
Rash maculo-papular 123.59 32.32 58 3607 46968 64448099
Toxic epidermal necrolysis 120.27 32.32 53 3612 37113 64457954
Alveolar lung disease 103.33 32.32 19 3646 518 64494549
Cholestasis 101.66 32.32 50 3615 44822 64450245
Pulmonary interstitial emphysema syndrome 93.07 32.32 17 3648 446 64494621
Pancytopenia 66.34 32.32 59 3606 143250 64351817
Diffuse alveolar damage 64.74 32.32 18 3647 3217 64491850
Eosinophilia 64.74 32.32 35 3630 38041 64457026
Agranulocytosis 59.09 32.32 33 3632 38196 64456871
Febrile bone marrow aplasia 56.54 32.32 22 3643 11233 64483834
Eosinophilic pneumonia 54.36 32.32 17 3648 4560 64490507
Drug reaction with eosinophilia and systemic symptoms 53.28 32.32 35 3630 54182 64440885
Thrombocytopenia 50.88 32.32 63 3602 223738 64271329
Hyperammonaemia 48.48 32.32 19 3646 9885 64485182
Generalised oedema 46.46 32.32 23 3642 20830 64474237
Aplasia 43.65 32.32 16 3649 6937 64488130
Housebound 43.51 32.32 9 3656 456 64494611
Confusional state 41.80 32.32 62 3603 261082 64233985
Hepatitis 38.96 32.32 27 3638 45555 64449512
Hepatic encephalopathy 37.56 32.32 20 3645 21046 64474021
Pancreatitis acute 35.73 32.32 25 3640 42830 64452237
Angioedema 33.72 32.32 28 3637 61793 64433274

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07XA04 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
OTHER ANTIDIARRHEALS
Other antidiarrheals
MeSH PA D000930 Antidiarrheals
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011480 Protease Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute diarrhea indication 409966000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neprilysin Enzyme INHIBITOR IC50 9 CHEMBL KEGG DRUG
Endothelin-converting enzyme 1 Enzyme IC50 8.10 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 6.50 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 6.38 CHEMBL
Neprilysin Enzyme IC50 8.32 CHEMBL
Neprilysin Enzyme IC50 8.40 CHEMBL
Neprilysin Enzyme IC50 8.21 CHEMBL
Thermolysin Enzyme IC50 5.02 CHEMBL

External reference:

IDSource
4025231 VUID
N0000179029 NUI
D08464 KEGG_DRUG
112573-73-6 SECONDARY_CAS_RN
16738 RXNORM
C0050461 UMLSCUI
CHEBI:91508 CHEBI
CHEBI:9568 CHEBI
TIO PDB_CHEM_ID
CHEMBL2103772 ChEMBL_ID
CHEMBL1516410 ChEMBL_ID
DB11696 DRUGBANK_ID
C049331 MESH_SUPPLEMENTAL_RECORD_UI
107751 PUBCHEM_CID
11654 IUPHAR_LIGAND_ID
5278 IUPHAR_LIGAND_ID
7378 INN_ID
76721-89-6 SECONDARY_CAS_RN
76K53XP4TO UNII
3132 PUBCHEM_CID
DB08626 DRUGBANK_ID
006079 NDDF
4025231 VANDF
C0039945 UMLSCUI
CHEMBL10247 ChEMBL_ID
6896 INN_ID
699272003 SNOMEDCT_US
714679008 SNOMEDCT_US
785287002 SNOMEDCT_US
D015244 MESH_DESCRIPTOR_UI
B79L7B5X3Z UNII

Pharmaceutical products:

None